Martin Julio
GlaxoSmithKline, Tres Cantos, Spain.
Curr Protoc Pharmacol. 2010 Sep;Chapter 9:Unit 9.13. doi: 10.1002/0471141755.ph0913s50.
Some drug targets are not amenable to screening because of the lack of a practical or validated biological assay. Likewise, some screening assays may not be predictive of compound activity in a more disease-relevant scenario, or assay development may demand excessive allocation of resources (i.e., time, money or personnel) with limited knowledge of the actual tractability of the target. Label-free methodologies, implemented in microtiter plate format, may help address these issues and complement, simplify, or facilitate assays. Label-free biosensors, based on grating resonance or electrical impedance, are versatile platforms for detecting phenotypic changes in both engineered and native cells. Their non-invasive nature allows for the kinetic monitoring of multiple real-time cellular responses to external stimuli, as well as for the use of successive pharmacological challenges. The temporal signature recorded for a particular stimulus is characteristic of the cell type and the signaling pathway activated upon binding of a ligand to its receptor. Cellular label-free technology is an important technical advance in the study of functional pharmacological selectivity. Described in this overview are some of the hurdles encountered in modern drug discovery and the ways in which label-free technologies can be used to overcome these obstacles.
由于缺乏实用的或经过验证的生物学检测方法,一些药物靶点无法进行筛选。同样,一些筛选检测方法可能无法预测化合物在更接近疾病实际情况中的活性,或者检测方法的开发可能需要在对靶点实际可操作性了解有限的情况下过度分配资源(即时间、金钱或人员)。以微孔板形式实施的无标记方法可能有助于解决这些问题,并补充、简化或促进检测。基于光栅共振或电阻抗的无标记生物传感器是检测工程细胞和天然细胞表型变化的通用平台。其非侵入性特点允许对细胞对外部刺激的多种实时反应进行动力学监测,以及进行连续的药理学挑战。针对特定刺激记录的时间特征是细胞类型以及配体与其受体结合后激活的信号通路的特征。细胞无标记技术是功能药理学选择性研究中的一项重要技术进展。本综述介绍了现代药物发现中遇到的一些障碍以及无标记技术用于克服这些障碍的方法。